Tesamorelin
Synthetic peptide studied in clinical and preclinical models for clinically proven visceral fat reduction and lipid profile
Last updated: March 1, 2026
- Compound
- Tesamorelin
- Class
- Body Composition peptide
- Summary
- Synthetic peptide studied in clinical and preclinical models for clinically proven visceral fat reduction, lipid profile, cognitive function support.
- Mechanism
- Metabolic Profile Improvement
- Research Status
- Approved
- Routes Studied
- Subcutaneous injection
- Evidence Level
- Clinically validated · Approved therapeutic
What Should You Know About Tesamorelin?
- What is Tesamorelin?
- Tesamorelin is a synthetic peptide studied in clinical and preclinical models for clinically proven visceral fat reduction and lipid profile.
- Is Tesamorelin clinically proven?
- Tesamorelin is an approved therapeutic with established clinical evidence.
- What has Tesamorelin been studied for?
- Tesamorelin has been studied in clinical and preclinical settings of clinically proven visceral fat reduction, lipid profile, cognitive function support and has received regulatory approval in at least one jurisdiction.
- Is Tesamorelin approved?
- Tesamorelin is an approved therapeutic in at least one jurisdiction. Regulatory status varies by country. Consult a local specialist for guidance.
What Is Tesamorelin?
Tesamorelin is a synthetic analogue of the 44-amino acid growth hormone-releasing hormone (GHRH), modified with a trans-3-hexenoic acid group attached to the tyrosine at position 1. This modification enhances the peptide's bioavailability and resistance to enzymatic degradation while preserving its ability to stimulate pulsatile growth hormone release from the anterior pituitary. Tesamorelin holds the distinction of being one of the few synthetic peptides to receive FDA approval, having been approved...
Evidence Summary
Tesamorelin is an approved therapeutic with established clinical evidence and regulatory approval in at least one jurisdiction.
Evidence Breakdown
| Domain | Evidence Level |
|---|---|
| Clinically Proven Visceral Fat Reduction | Limited |
| Lipid Profile | Limited |
| Cognitive Function Support | Limited |
| Physiological GH Optimization | Limited |
| Human clinical evidence | Established |
| Safety data | Established |
Editorial Position
Tesamorelin is an approved therapeutic with established clinical evidence. As with any pharmaceutical compound, individual suitability should be discussed with a specialist.
Regulatory Status Snapshot
- Approved as a therapeutic drug in at least one jurisdiction
- Safety and efficacy established through regulatory review processes
Need help interpreting this evidence for your situation?
Talk to a SpecialistA deep research review for Tesamorelin is not yet available. This compound profile is based on published peer-reviewed references listed below.
Browse all research reviewsWhat Has Tesamorelin Been Studied For?
Research areas where Tesamorelin has been investigated in published studies
-
Clinically Proven Visceral Fat Reduction Tesamorelin has been studied in clinical and preclinical studies of clinically proven visceral fat reduction.
-
Lipid Profile Tesamorelin has been studied in clinical and preclinical studies of lipid profile.
-
Cognitive Function Support Tesamorelin has been studied in clinical and preclinical studies of cognitive function support.
-
Physiological GH Optimization Tesamorelin has been studied in clinical and preclinical studies of physiological gh optimization.
How Does Tesamorelin Work?
These mechanisms have been established through clinical and preclinical research.
- 01 GHRH Receptor Agonism
- 02 Pulsatile GH Secretion
- 03 IGF-1 Production & Lipolysis
- 04 Visceral Fat Reduction
Not sure if Tesamorelin is right for you?
A specialist can review the evidence, evaluate your medical context, and help you make an informed decision about Tesamorelin.
Community Reports (Anecdotal)
Experiences shared here are self-reported and do not represent clinical evidence.
Rate Tesamorelin
How Is Tesamorelin Administered?
Tesamorelin is available via Subcutaneous injection, auto-injector pen. Appropriate use and protocol should be determined by a qualified specialist.
What Are the Specifications of Tesamorelin?
What Conditions Has Tesamorelin Been Linked To?
Have Questions About Tesamorelin?
Clinical trials demonstrated an average 15-18% reduction in visceral (trunk) fat over treatment periods, measured by CT imaging. Changes typically become measurable after 4-6 weeks. Tesamorelin also supports lean tissue maintenance through GH-mediated protein synthesis.
Research from Harvard Medical School published in JAMA Neurology demonstrated that 20 weeks of tesamorelin treatment improved executive function, verbal memory, and reduced cognitive complaints in older adults compared to placebo.
Published studies on Tesamorelin can be found on PubMed and other peer-reviewed databases. Our references section below lists key citations.
Ready to discuss Tesamorelin with a specialist?
Get evidence-based guidance tailored to your health goals and medical context.
Book a Consultation Free initial consultation. No obligation.Reviewed by the Peptide Science Thailand Editorial Team.
Last reviewed: March 1, 2026